News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features Roughly 80% of ESC Guideline Writers Have Financial COIs Michael O'Riordan April 01, 2021
News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020